Contrast-induced Nephropathy Clinical Trial
Official title:
Comparison of Carvedilol and Atorvastatin for Prevention of Contrast-Induced Nephropathy After Cardiac Catheterization
This prospective study is intended to evaluate if carvedilol has any potential protective effect over atorvastatin on the development of contrast-induced nephropathy (CIN) following cardiac catheterization in patients with moderate to high risk for CIN.
This study enrolled 150 patients planned for CC, and randomly assigned for one of the three groups. Group (A)include 49 patients who received two atorvastatin dose 80 mg 12 hours before CC and 40 mg just before CC. Group (B) include 48 patients who received 12.5 mg carvedilol twice daily for 7 days before CC and continue for 24hrs after the day of CC, Group (C) include 47 patients who only hydrated with saline. All included patients were hydrated with saline intravenous 0.9 sodium chloride (NaCl) at 0.5-1 mg/kg/hour for 4-6 hours before and 4-6 hours after cardiac catheterization. Serum creatinine(Scr), blood urea nitrogen (BUN) and estimated glomerular filtration rate were evaluated at the baseline and after 48 from CC. Serum neutrophil-associated lipocalin (NGAL) was evaluated after 4 hours from CC. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04877847 -
Multi-Center Trial Utilizing Low Frequency Ultrasound in the Prevention of Post-Contrast Acute Kidney Injury
|
N/A | |
Recruiting |
NCT02088502 -
Theophylline, N-acetylcysteine, and Theophylline Plus N-acetylcysteine in Preventing Contrast-induced Nephropathy
|
Phase 2/Phase 3 | |
Completed |
NCT03329443 -
The Effect of Spironolactone on Acute Kidney Injury in Patients Undergoing Coronary Angiography
|
Phase 2 | |
Recruiting |
NCT04864847 -
Clinical Validation of the RENISCHEM L-FABP POC Assay
|
||
Completed |
NCT03627130 -
The Use of Inorganic Nitrate for the Prevention of Contrast-induced Nephropathy
|
Phase 2 | |
Active, not recruiting |
NCT03736018 -
Randomised Controlled Trial to Assess Whether Computed Tomography Cardiac Angiography Can Improve Invasive Coronary Angiography in Bypass Surgery Patients
|
N/A | |
Withdrawn |
NCT04598516 -
Maastricht Investigation of Renal Function in Absence of- and Post- Contrast in Patients With eGFR LEss Than 30
|
||
Withdrawn |
NCT04603261 -
Time to Excretion of Contrast, a Maastricht Prospective Observational Study
|
||
Recruiting |
NCT03755700 -
Vitamin E and N-acetylcysteine for Preventing Contrast-Induced Acute Kidney Injury After Coronary Artery Catheterization
|
Phase 3 | |
Active, not recruiting |
NCT04606056 -
Risk of Acute Kidney Injury After Intravenous Contrast Computed Tomography Scans
|
||
Terminated |
NCT02440646 -
Natural History of Coronary Atherosclerosis in Real-World Stable Chest Pain Patients Underwent Computed Tomography Angiography in Comparison With Invasive Multimodality Imaging
|
||
Completed |
NCT00175227 -
Prevention of Contrast-Induced Nephropathy
|
N/A | |
Completed |
NCT04014153 -
CI-AKI in Patients With Stable CAD and Comorbidities. Are we Doing Better?
|
||
Withdrawn |
NCT04597892 -
Efficacy of Point-Of-Care Creatinine Assays in Patients With eGFR <30 Receiving Intravascular Contrast
|
||
Completed |
NCT03305874 -
Automated Prediction and Prevention of Contrast Induced Nephropathy After Cardiac Catheterization
|
||
Not yet recruiting |
NCT01871792 -
Preventive Effect of Pitavastatin on Contrast-Induced Nephropathy in Patients With Renal Dysfunction
|
Phase 4 | |
Not yet recruiting |
NCT06429345 -
Coenzyme Q10 Role in Prevention of Contrast Induced Nephropathy in Acute Coronary Syndrome Patients.
|
Phase 4 | |
Recruiting |
NCT05271448 -
Continuing or Discontinuing ACE/ARBs in Patients With Chronic Kidney Disease Undergoing Coronary Angiography
|
N/A | |
Withdrawn |
NCT03806725 -
Safety of Iodinated Contrast in Liver Transplant Candidates With Decreased Renal Function Undergoing Coronary CT Angiography
|
||
Completed |
NCT04163250 -
Use of Urinary Cell-Cycle Arrest Biomarkers in Contrast-Associated Nephropathy After Coronary Angiography
|